Imagion Biosystems Limited is pleased to share news of research published by collaborators from the University of Sydney demonstrating that Imagion’s iron oxide nanoparticles enable low-field magnetic resonance imaging, which could provide a significant advancement in medical imaging by reducing the cost and improving the accessibility of MRI. This research reinforces the significance of the clinical and commercial opportunity for Imagion’s nanoparticles.
Dr. Nina Webster Joins IBX Board of Directors
September 1, 2025
Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilizing its proprietary MagSense® imaging